Condition: Endogenous Cushing Syndrome · Adrenal Insufficiency · Hypercortisolism · Sponsor: University of Michigan
The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach). The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.
This description comes directly from the study's public registry record.
Richard Auchus · 734-764-7764 · rauchus@med.umich.edu
Thaira Blanco Varela · 734-647-5661 · tbv@med.umich.edu
Always discuss trial participation with your own doctor first.
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06430528